McKesson stock
MCKNYSEMcKesson Corporation, HealthcareISIN US58155Q1031
75Score 75 out of 100, Strong
Price and trend
85 / 100
Price history
+28% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 23% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 70).
The price is at its 52-week high. Largest decline in 20 years: 58% (January 2008 to November 2008).
Chart figures for advanced users
- SMA 50$951.46
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$872.85
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)70
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$725.17
- The lowest closing price of the last twelve months.
- Resistance$1,082.59
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- McKesson Corporation belongs to the Medical (Distribution) industry (United States) and, with a market value of $124.35B, is the largest of 17 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $403.43B (up 12.4% year on year) and earnings of $4.76B (up 44.5%).
- For fiscal 2027, analysts expect on average revenue of $433.28B (up 7.4%) and adjusted earnings per share of $45.16 (up 15.3%).
Show more
- MEQIRI Score 75 out of 100 (Strong): rank 72 of 702 in Healthcare, median 53.
- The P/E is 26.7 (Medical (Distribution) median 26.8, own median of recent years 23.8).
- Our model puts fair value at $1,175.00, with the price 8% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 33.9% in fiscal 2026, Medical (Distribution) median 7.3%.
- Share buybacksShare count down 23% since 2021.Capital allocation 99
- Reliable dividendNo dividend cut for 27 years.Capital allocation 99
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are capital allocation and fundamentals, while profitability holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 76 to 75.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $903.85 and expensive above $1,678.58 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $1,270.26 (cash-flow model) and $1,079.75 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly below both parts; given how much the stock swings, that still counts as fair.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $1,066.59, at 7.8% it would be $1,337.83.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (26.8).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 8.2% on the twelve months before. Revenue has grown solidly since 2007, at about 8% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 4%, operating 2%, net 1%.
Debt & balance sheet
latest quarterMeaningfully leveraged, but the interest bill is comfortably covered.
Earnings
- Next earnings
- 3 Feb 2027in 82 days
- Last reported
- 4 Nov 2026EPS reported $11.68 (expected $10.72)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $45.16+1.1%
- Revenue
- $433.28B+0.3%
- Earnings per share
- $51.37+1.4%
- Revenue
- $462.87B+0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +4.9%Fiscal 2027 adjusted EPS guidance raised to $44.20 to $45; revenue growth of 5% to 9% and operating profit growth of 9% to 13% expected.
“For fiscal 27, we anticipate revenue growth of 5% to 9% and operating profit growth of 9% to 13%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q1 2027), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 7 insiders sold, $26.1M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Fraga FranciscoSale
5 Nov 2026, EVP, CIO and CTO
- Shares
- 650
- Price
- $1,102.96
- Value
- $716,924
- Fraga FranciscoSale
4 Nov 2026, EVP, CIO and CTO
- Shares
- 600
- Price
- $1,050.00
- Value
- $630,000
- Fraga FranciscoSale
15 Oct 2026, EVP, CIO and CTO
- Shares
- 800.49
- Price
- $995.80
- Value
- $797,129
Show 11 more
- Rutledge Napoleon B JRSale
8 Sept 2026, SVP, Controller & CAO
- Shares
- 111
- Price
- $891.45
- Value
- $98,951
- Lerman Bradley ESale
10 Aug 2026, Board
- Shares
- 301
- Price
- $892.33
- Value
- $268,590
- Tyler Brian S.Sale
7 Jul 2026, Chief Executive Officer
- Shares
- 8,463
- Price
- $793.56
- Value
- $6.72M
- Tyler Brian S.Sale
17 Jun 2026, Chief Executive Officer
- Shares
- 8,463
- Price
- $775.13
- Value
- $6.56M
- Tyler Brian S.Sale
9 Jun 2026, Chief Executive Officer
- Shares
- 4,929
- Price
- $763.00
- Value
- $3.76M
- Rutledge Napoleon B JRSale
5 Jun 2026, SVP, Controller & CAO
- Shares
- 133
- Price
- $764.00
- Value
- $101,612
- Rodgers Thomas LSale
2 Jun 2026, EVP, Chief Strategy & BDO
- Shares
- 699
- Price
- $735.27
- Value
- $513,954
- Rodgers Thomas LSale
1 Jun 2026, EVP, Chief Strategy & BDO
- Shares
- 123
- Price
- $735.50
- Value
- $90,467
- Smith LeAnn BSale
1 Jun 2026, EVP & Chief HR Officer
- Shares
- 1,810
- Price
- $735.50
- Value
- $1.33M
- Lau MicheleSale
26 May 2026, EVP and Chief Legal Officer
- Shares
- 3,550
- Price
- $761.09
- Value
- $2.7M
- Rodgers Thomas LSale
26 May 2026, EVP, Chief Strategy & BDO
- Shares
- 2,388
- Price
- $761.09
- Value
- $1.82M
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at McKesson
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 75
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Distribution)
The next smaller companies by market value
- CencoraCOR $66.67B74
- Cardinal HealthCAH $64.29B68
- Henry ScheinHSIC $9.52B65
- Shanghai Pharmaceuticals Holding601607.SS $9.04B53
- Sinopharm Group1099.HK $6.63B58
- GalenicaGALE.SW $5.42B59
- AmplifonAMP.MI $3.47B47
- Asker Healthcare GroupASKER.ST $2.8B61
ETFs that hold McKesson
Held by 112 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 2.10% | 0.18% | €839.61M |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 1.87% | 0.15% | €599.59M |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 1.84% | 0.12% | €1.39B |
Show 5 more
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 1.84% | 0.15% | €3.29B |
| iShares Edge MSCI USA Minimum Volatility Advanced UCITS ETFMVEA | 1.81% | 0.20% | €119.49M |
| Harbor Health Care UCITS ETF AccW311 | 1.70% | 0.89% | €11.72M |
| iShares STOXX World Equity Multifactor UCITS ETFIBCZ | 1.68% | 0.30% | €826.24M |
| iShares STOXX USA Equity Multifactor UCITS ETFIBCY | 1.41% | 0.20% | €48.79M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.